Ritrosulfan

This classification denotes an antineoplastic alkylating agent with the molecular formula C10H24N2O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YIY0662KX9, chemically known as 3,14-dioxa-2,15-dithia-6,11-diazahexadecane-8,9-diol, 2,2,15,15-tetraoxide, (r*,s*)- (9ci) but more generally known as ritrosulfan, which bears US NIH Compound Identifier 20107. European Medicines Agency schedules Ritrosulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10344MIG. The term RITROSULFAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). RITROSULFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ritrosulfan under HS 29221980 and SITC 51461. As of Q4 2014, RITROSULFAN remains US FDA's Preferred Term for this commodity. Ritrosulfan bears US NLM identifiers UMLS ID C0073401 and NCI Concept Code C75294. SMILES: CS(=O)(=O)OCCNCC(C(CNCCOS(=O)(=O)C)O)O.